Evidence map›Paper›PMID 37109441›Full record

ArticleLife (Basel, Switzerland)2023

Synthesis and in Silico Investigation of Organoselenium-Clubbed Schiff Bases as Potential M

Saad Shaaban, Aly Abdou, Abdulrahman G Alhamzani, Mortaga M Abou-Krisha, Mahmoud A Al-Qudah, Mohamed Alaasar, Ibrahim Youssef, Tarek A Yousef

Abstract read
In one paragraph

Article in Life (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed.

  1. Article
  2. Article
  3. New 1,3-diphenyl-1Heliyon · 2024
    Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. In Silico Models for Anti-COVID-19 Drug Discovery: A Systematic Review.Advances in pharmacological and pharmaceutical sciences · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Saad ShaabanDepartment of Chemistry, College of Science, King Faisal University, Al-Ahsa 31982, Saudi Arabia.
Aly AbdouDepartment of Chemistry, Faculty of Science, Sohag University, Sohag 82524, Egypt.ORCID 0000-0002-5979-2650
Abdulrahman G AlhamzaniCollege of Science, Chemistry Department, Imam Mohammad Ibn Saud Islamic University, Riyadh 11623, Saudi Arabia.ORCID 0000-0002-5116-3622
Mortaga M Abou-KrishaCollege of Science, Chemistry Department, Imam Mohammad Ibn Saud Islamic University, Riyadh 11623, Saudi Arabia.ORCID 0000-0003-2224-8165
Mahmoud A Al-QudahCollege of Science, Chemistry Department, Imam Mohammad Ibn Saud Islamic University, Riyadh 11623, Saudi Arabia.ORCID 0000-0001-7179-8249
Mohamed AlaasarInstitute of Chemistry, Martin Luther University Halle-Wittenberg, 06108 Halle (Saale), Germany.ORCID 0000-0003-4155-8644
Ibrahim YoussefDepartment of Chemistry, Faculty of Science, Mansoura University, Mansoura 35516, Egypt.ORCID 0000-0003-2228-0368
Tarek A YousefCollege of Science, Chemistry Department, Imam Mohammad Ibn Saud Islamic University, Riyadh 11623, Saudi Arabia.ORCID 0000-0003-3039-7646

Funding

Imam Muhammad ibn Saud Islamic University Grant No. (21-13-18-065)
6 · The paper itself

Abstract

Since the first report of the organoselenium compound, ebselen, as a potent inhibitor of the SARS-CoV-2 M

Indexed as

ADMETCOVID-19DFTdockingorganoseleniumSARS-CoV-2Schiff base

Identifiers

PMID37109441
PMCPMC10141725

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.